Search

Repligen Corp

Lezárt

SzektorEgészségügy

167.69 1.09

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

167.01

Maximum

168.35

Fő mutatók

By Trading Economics

Bevétel

-43M

-38M

Értékesítés

5.2M

209M

P/E

Szektor átlag

243.473

68.089

Egy részvényre jutó nyereség

0.53

Profit margin

-18.361

Munkavállalók

2,000

EBITDA

-48M

-2M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+25.33% upside

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-546K

11B

Előző nyitás

166.6

Előző zárás

167.69

Repligen Corp Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. nov. 12. 21:07 UTC

Repligen Corporation shares fell significantly, reaching a low of nearly 4.3% before slightly recovering, amid broader market trends and trading below its 20-day moving average.

2026. nov. 11. 21:13 UTC

Repligen Corporation shares traded modestly lower during after-market hours on Wednesday, continuing a trend of three consecutive daily declines.

2026. nov. 9. 21:03 UTC

Repligen Corporation is trading significantly higher, with a notable gain since Friday's close, and remains well above its 20-day moving average.

2026. nov. 6. 21:06 UTC

Repligen Corporation's shares advanced during Friday's trading session, reflecting a notable gain since Thursday's close, despite pulling back from a midday peak.

2026. nov. 5. 21:04 UTC

Correlated Moves

Repligen Corporation shares fell sharply, reflecting a broader downturn in the ARK Genomic Revolution ETF, which is facing significant losses in several holdings.

2026. nov. 4. 21:21 UTC

Repligen Corporation's shares declined in after-market trading, retreating from a brief peak at Wednesday's close to a notable low within its one-month trading range.

2026. nov. 3. 21:07 UTC

Correlated Moves

Repligen Corporation shares are higher, supported by a rise in Revvity, Inc. following its strong third-quarter results that exceeded analyst expectations.

2026. nov. 2. 21:09 UTC

Correlated Moves

Repligen Corporation shares are declining amid a broader market downturn, trading well below their 20-day moving average following an early spike that quickly reversed.

2026. okt. 30. 20:03 UTC

News

Repligen Corporation announced a $1 billion issuance of Convertible Senior Notes due 2031, with plans to repurchase shares using $120 million of the proceeds.

2026. okt. 29. 20:02 UTC

Repligen Corporation shares are advancing, remaining significantly above their 20-day moving average and near the upper end of their one-month range.

2026. okt. 28. 23:03 UTC

Repligen Corporation is advancing in after-market trading, showing strong performance since Wednesday's close and trading near the upper end of its one-month range.

2026. okt. 27. 20:01 UTC

News

Repligen Corporation reported Q3 adjusted EPS of $0.53 and revenue of $209.31 million, while narrowing FY 2026 EPS guidance amid a $38.4 million loss.

2026. okt. 26. 20:07 UTC

Correlated Moves

Repligen Corp shares are higher, following an upward trend in Charles River Laboratories, which is benefiting from positive developments in its product pipeline.

2026. okt. 23. 19:16 UTC

Repligen Corp shares are declining, having pulled back from earlier gains and currently trading significantly below their 20-day moving average.

2026. okt. 22. 20:07 UTC

Correlated Moves

Repligen Corp shares are declining amid a broader downturn in the Life Sciences Tools & Services sector, pulling back from earlier session highs.

2026. okt. 21. 20:07 UTC

Correlated Moves

Repligen Corp's shares are advancing, regaining momentum after an earlier pullback, alongside a broader market rise and notable trading activity in Charles River Laboratories.

2026. okt. 20. 20:08 UTC

Repligen Corp shares are advancing, continuing a trend higher since Monday's close, despite earlier pulling back from a session high.

2026. okt. 19. 19:36 UTC

News

Canaccord Genuity raises Repligen Corp's price target to $180.00 from $145.00 while maintaining a Hold rating, reflecting a positive reassessment of the company's value.

2026. okt. 16. 22:01 UTC

Repligen Corp is trading lower in after-market hours, following a notable decline since Friday's close amid unusual volatility and positioning near its one-month range low.

2026. okt. 15. 20:07 UTC

Repligen Corp shares advanced, reaching a peak before the session's conclusion.

2026. okt. 14. 20:07 UTC

Repligen Corp shares are advancing, benefiting from broader market gains, despite pulling back from earlier session highs. The stock is higher since Tuesday's close.

2026. okt. 13. 20:07 UTC

News

Repligen Corp shares are advancing as the company prepares to report its third-quarter 2026 financial results on October 27, 2026.

2026. okt. 12. 21:03 UTC

Repligen Corp shares advanced during after-market hours on Monday, moving from a low return to a high return.

2026. okt. 9. 20:01 UTC

Repligen Corp shares are sharply higher, continuing an upward trajectory since Thursday's close, supported by positive movement in the broader life sciences sector.

2026. okt. 8. 20:07 UTC

Repligen Corp shares fell sharply, continuing a downward trend with three consecutive sessions down, despite a brief recovery earlier in the session.

2026. okt. 7. 20:01 UTC

News

Repligen Corp. finalized its $1.5 billion acquisition of BioLife Solutions, but shares fell sharply amid ongoing declines following a prior session drop.

2026. okt. 6. 21:01 UTC

Repligen Corp's shares traded modestly higher in after-market hours, marking a peak since Tuesday's close despite remaining below the 20-day moving average.

2026. okt. 5. 22:15 UTC

News

Repligen Corp plans to acquire BioLife Solutions, contributing to a modest after-market hours gain as the stock remains above its 20-day moving average.

2026. okt. 2. 20:07 UTC

Repligen Corp's shares are advancing, reflecting a broader market trend, maintaining strong performance above the 20-day moving average amid notable intraday volatility.

2026. okt. 1. 20:02 UTC

Repligen Corp shares fell sharply, breaking a trend of higher daily closes and diverging from recent upward momentum.

Társak összehasonlítása

Árváltozás

Repligen Corp Előrejelzés

Célár

By TipRanks

25.33% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 210.286 USD  25.33%

Magas 235 USD

Alacsony 180 USD

8 Wall Street elemző 12 hónapos célárain alapulva a(z)Repligen Corp termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

8 ratings

7

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
help-icon Live chat